Clinical trial
Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab…
NCT00390416 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00390416 |
|---|---|
| Title | Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma |
| Official title | A Phase II Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | Sanofi Industry Genentech, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stomach Neoplasms, Esophageal Neoplasms |
| Intervention type | Drug |
| Interventions | Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin |
| Enrollment | 48 |
| Start date | Oct 1, 2006 |
| Primary completion | Jan 1, 2012 |
| Completion | Jan 1, 2012 |
| First posted | Oct 19, 2006 |
| Last update posted | Mar 14, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: